Form 4: aTyr Pharma CEO Acquires 1 Million Stock Options

aTyr Pharma's CEO, Sanjay Shukla, was granted 1 million stock options with a vesting schedule starting February 8, 2025.

Summary

• Sanjay Shukla, the President and CEO of aTyr Pharma, was granted 1,000,000 employee stock options.
• The options have an exercise price of $3.74 per share.
• The options vest in 48 equal monthly installments starting February 8, 2025, and will be fully vested by January 8, 2029.
• The options expire on January 8, 2035.
• The options are subject to accelerated vesting upon termination without cause following a change of control of the issuer.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry.
• The vesting schedule of 48 months is typical for such grants, encouraging long-term performance.
• The exercise price of $3.74 is specific to aTyr Pharma's stock and market conditions at the time of the grant.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, atyr pharma, Sanjay Shukla, equity